RecruitingNCT06427317
Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment
Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment and the Potential Role of Therapeutic Drug Monitoring in UK Infection Management
Sponsor
Imperial College London
Enrollment
323 participants
Start Date
Mar 19, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The primary aim of the study is to determine the proportion of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust in whom drug concentration targets are achieved.
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- years of age or above.
- Under follow-up for management of infection at Imperial College NHS Trust
- Received a beta-lactam antibiotic within the last 48 hours (or are planned to start imminently).
- Provides informed written consent see below, or lacks capacity to provide consent because of one of the following conditions (and declaration provided by personal consultee):
- Delirium which may be caused or exacerbated by having an infection.
- Suspected/confirmed central nervous system infection.
- Critical illness requiring sedation and/or intubation and ventilation which is caused by or exacerbated by having an infection.
Exclusion Criteria6
- Less than 18 years of age
- Severe anaemia (Hb < 70g/l)
- Platelets < 50x10\^9/l, INR >1.5 or other known blood clotting impairment
- Patient with terminal diagnosis receiving palliative care input who may experience distress if approached for this study.
- Enrolled in a clinical trial which stipulates exclusion from other studies including observational studies.
- Patients with restricted liberty, prisoners or under legal protection.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06427317
Related Trials
Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies
NCT046697171 location
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers
NCT075601501 location
IMMUNO-FIT Observational Study
NCT073549711 location
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT0716985166 locations
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
NCT074222855 locations